Bank Julius Baer & Co. Ltd, Zurich Novavax Inc Transaction History

Bank Julius Baer & Co. Ltd, Zurich

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$69.73 - $142.9 $227,180 - $465,568	-3,258 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$134.56 - $217.97 $557,347 - $902,831	-4,142 Reduced 55.97%	3,258 $466,000
Q3 2021 Nov 12, 2021	BUY	$177.8 - $270.58 $783,920 - $1.19 Million	4,409 Added 147.41%	7,400 $1.54 Million
Q2 2021 Jul 23, 2021	BUY	$121.0 - $257.67 $319,561 - $680,506	2,641 Added 754.57%	2,991 $635,000
Q1 2021 May 10, 2021	SELL	$112.98 - $319.93 $585,575 - $1.66 Million	-5,183 Reduced 93.67%	350 $64,000
Q4 2020 Feb 24, 2021	SELL	$78.74 - $139.5 $1.62 Million - $2.87 Million	-20,541 Reduced 78.78%	5,533 $617,000
Q4 2020 Feb 12, 2021	BUY	$78.74 - $139.5 $1.62 Million - $2.87 Million	20,574 Added 374.07%	26,074 $617,000
Q3 2020 Nov 10, 2020	SELL	$79.44 - $178.51 $148,473 - $333,635	-1,869 Reduced 25.36%	5,500 $596,000
Q2 2020 Aug 12, 2020	SELL	$13.86 - $83.61 $416,465 - $2.51 Million	-30,048 Reduced 80.31%	7,369 $617,000
Q1 2020 May 13, 2020	BUY	$3.93 - $16.0 $147,048 - $598,672	37,417 New	37,417 $508,000

292

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.